Fibrosis & IPF:
A while back I wondered about FGEN trying to use that as a primary end point to go head to head with the approved agents (I don't see it as very likely at this point perhaps it will be a secondary endpoint). I did find a couple papers looking at past studies where I believe HRCT was primarily used to screen patients for entry in the trial. An interesting finding was that the extent of fibrosis was by far the biggest predictor of mortality, followed by DLCO (not FVC).
The paper is a bit older (2004) it should be available online but I don't have a link handy its
High-Resolution Computed Tomography in Idiopathic
Pulmonary Fibrosis
David A. Lynch, J. David Godwin, Sharon Safrin, Karen M. Starko, Phil Hormel, Kevin K. Brown,
Ganesh Raghu, Talmadge E. King, Jr., Williamson Z. Bradford, David A. Schwartz, and W. Richard Webb,
for the Idiopathic Pulmonary Fibrosis Study Group
